GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CytomX Therapeutics
CytomX is a biotech company developing a new generation of targeted cancer therapies. Its stock price is volatile and depends on the results of clinical trials and partnerships with major pharmaceutical companies that validate its technology platform.
Share prices of companies in the market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anticancer drugs—proantibodies that are activated only in the tumor environment, reducing side effects. We've classified it in the "Oncology Platforms" segment. The chart below shows the overall dynamics of innovative oncology platforms, which promise safer cancer treatment.
Broad Market Index - GURU.Markets
CytomX Therapeutics is an oncology company developing a new class of drugs—proantibodies that are activated only in tumors to reduce side effects. As part of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CTMX - Daily change in the company's share price CytomX Therapeutics
The daily price change of CytomX, an oncology company, is a measure of its sensitivity to clinical trial results. Change_co reflects the high volatility inherent in the biotech sector. This metric is important for formulas on System.GURU.Markets that analyze companies developing innovative cancer treatment platforms.
Daily change in the price of a set of shares in a market segment - Oncology platforms
CytomX Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with CTMX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
CytomX is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows average fluctuations in this industry, providing context for evaluating CytomX shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CytomX Therapeutics
CytomX Therapeutics' year-to-date performance is a story about the development of "smart" anti-cancer drugs that are activated only in tumors. Its 12-month market cap depends on clinical trial data and partnerships with major pharmaceutical companies. The success of its Probody platform could fundamentally change the approach to targeted therapy safety.
Annual dynamics of market capitalization of the market segment - Oncology platforms
CytomX Therapeutics, Inc. is a biotech company developing a new class of immunotherapeutic drugs that are activated only in tumors. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CytomX is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its innovative cancer treatment platform. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CytomX Therapeutics
The dynamics of CytomX, a biopharmaceutical company, are speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its oncology drugs based on its unique platform, and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs—probodies that activate only in tumors, reducing side effects. This is an innovative platform. The oncology sector's performance reflects the general investor interest in breakthrough technologies, providing a backdrop for assessing the scientific potential and risks associated with CytomX's approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CytomX Therapeutics is developing a new generation of cancer drugs that are activated directly by tumors. This is a high-risk biotech bet. The company's stock price responds not to market cycles, but to the publication of research data. The chart will show how scientific successes and failures shape its own story, independent of the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CytomX Therapeutics
CytomX Therapeutics is developing a new generation of "smart" cancer drugs that are activated only in tumors. Its weekly stock price reflects investor confidence in this complex technology, bolstered by news of clinical trial data and partnerships with pharmaceutical giants.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Biotech companies developing platform technologies in oncology, like CytomX, are driven by investor confidence in their scientific approach. The chart below illustrates the general sentiment in this niche. It allows one to assess how promising the market perceives CytomX's smart antibody technology compared to competitors' platforms.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CytomX Therapeutics is developing a new generation of "smart" cancer drugs that are activated only in tumors. This is a cutting-edge scientific concept. The chart shows that the company's stock is living in anticipation of clinical data, and its dynamics are completely disconnected from overall market trends.
Market capitalization of the company, segment and market as a whole
CTMX - Market capitalization of the company CytomX Therapeutics
CytomX Therapeutics' market capitalization reflects investors' bets on its innovative proantibody platform. The chart reflects the market's belief that its technology, which activates drugs only within tumors, will make cancer treatment safer and more effective. Its value is an estimate of the platform's potential and its partnerships with major pharmaceutical companies.
CTMX - Share of the company's market capitalization CytomX Therapeutics within the market segment - Oncology platforms
CytomX Therapeutics is developing an innovative class of anti-cancer antibodies that are activated only within tumors. In the oncology platform segment, its market cap reflects the potential of this technology to minimize the side effects of chemotherapy. Its growth reflects investor confidence that this approach will be a breakthrough in cancer treatment.
Market capitalization of the market segment - Oncology platforms
This chart shows the overall value of the entire biotech sector focused on oncology platforms. For CytomX, with its smart antibody technology that activates only in tumors, this line represents the future of chemotherapy. The rising chart reflects investors' belief that new approaches will make cancer treatment more precise and less toxic.
Market capitalization of all companies included in a broad market index - GURU.Markets
CytomX Therapeutics develops "smart" cancer drugs that are activated only in tumors. Its market capitalization is the valuation of its technology, which minimizes side effects. This represents the share of the overall market that investors are allocating to safer and more precise oncology.
Book value capitalization of the company, segment and market as a whole
CTMX - Book value capitalization of the company CytomX Therapeutics
CytomX Therapeutics is developing a new class of anti-cancer antibodies—probodies. Its book value is its financial and scientific capital. It consists of cash for R&D and the value of its unique technology platform. How has this capital changed as innovation progressed? The chart below shows this story.
CTMX - Share of the company's book capitalization CytomX Therapeutics within the market segment - Oncology platforms
CytomX Therapeutics is a biotech company developing smart cancer drugs. Its innovations require a substantial infrastructure: cutting-edge laboratories and its own Probody platform for developing conditionally activated antibodies. The chart shows the company's share of the physical R&D infrastructure in this oncology segment.
Market segment balance sheet capitalization - Oncology platforms
CytomX Therapeutics, a biopharmaceutical company, is developing a new generation of antibodies. Its business is capital-intensive from a scientific perspective. The BCap_Seg chart for the biotech sector shows that the industry as a whole relies on expensive laboratories to create breakthrough technologies.
Book value of all companies included in the broad market index - GURU.Markets
CytomX's balance sheet isn't the drugs on its shelves, but its unique scientific platform, Probody®, for creating "smart" anti-cancer antibodies that activate only in tumors. The company's assets are its intellectual capital. The chart shows how this intangible yet valuable R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CytomX Therapeutics
CytomX's balance sheet is its R&D capital. Its entire market value is a premium on its Probody® scientific platform, which promises to create safer and more effective cancer drugs. The schedule is a bet on the success of this innovative technology.
Market to book capitalization ratio in a market segment - Oncology platforms
CytomX Therapeutics is developing a new class of anticancer drugs that are activated only in tumors. Its high score on this chart reflects its innovative platform, which could make the therapy safer and more effective while reducing side effects.
Market to book capitalization ratio for the market as a whole
CytomX Therapeutics is developing a new class of cancer drugs—proantibodies. The company's value lies in its scientific platform and partnerships with major pharmaceutical companies. Its market capitalization is a multiple of its book value, reflecting the company's high expectations for the success of its innovative approach to oncology.
Debts of the company, segment and market as a whole
CTMX - Company debts CytomX Therapeutics
CytomX Therapeutics, an oncology company developing innovative "prodrugs" that are activated only in tumors, is using capital to fund its unique scientific platform. This chart shows how the company is raising funds to conduct clinical trials that can prove the efficacy and safety of its new approach to cancer treatment.
Market segment debts - Oncology platforms
CytomX Therapeutics is a biotech company developing a new generation of targeted cancer drugs. Debt financing is rare during clinical development due to the high risks involved. This chart likely shows that the company, like its peers in the sector, relies on equity to fund its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CytomX Therapeutics
CytomX Therapeutics develops innovative cancer treatment platforms. This requires significant long-term investment. This chart shows the extent to which the company finances its cutting-edge research with debt. It reflects a classic biotech situation, where high financial risk is the price to pay for the potential to create breakthrough drugs.
Market segment debt to market segment book capitalization - Oncology platforms
CytomX Therapeutics is developing a new class of cancer drugs (proantibodies) that are activated only within the tumor, reducing side effects. This is a promising but complex technology. The chart shows how the biotech sector uses debt for R&D, which helps understand how CytomX funds its research.
Debt to book value of all companies in the market
CytomX Therapeutics is developing a new generation of cancer drugs, which entails high R&D costs and a lengthy approval cycle. This chart, showing the market's overall debt load, allows one to assess the company's financial stability. It helps understand how CytomX finances its innovations and how its debt policy relates to biotech risks.
P/E of the company, segment and market as a whole
P/E - CytomX Therapeutics
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs called Probodies, which are activated only in tumors. This chart shows the market value of its innovative platform. This value depends on clinical trial success and the potential of this technology to improve the safety and effectiveness of cancer treatment.
P/E of the market segment - Oncology platforms
CytomX Therapeutics develops "smart" cancer drugs. This chart shows the average valuation for the biotech sector. It emphasizes that CytomX is valued not by profit, but by the potential of its innovative Probody platform to make cancer treatment safer, which the market may value at a significant premium.
P/E of the market as a whole
CytomX Therapeutics is an oncology company developing a new generation of targeted therapies called Probodies, which are activated only in tumors, reducing side effects. This chart reflects the overall risk appetite of biotech investors. It helps us understand whether CTMX's high valuation is based on faith in its unique platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CytomX Therapeutics
CytomX Therapeutics is developing a new class of targeted anticancer drugs that are activated only in tumors. Future revenue depends on the success of this innovative platform. This chart reflects market expectations regarding the potential of its technology to make therapy safer and more effective.
%20P%2FE%20CytomX%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CytomX-Therapeutics&v=1772616412671 "Chart of the company's future (projected) P/E CytomX Therapeutics")
Future (projected) P/E of the market segment - Oncology platforms
CytomX Therapeutics is developing an innovative class of anticancer drugs called Probody, which are activated only within the tumor environment, potentially reducing side effects. The data presented here reflects the collective analyst consensus on the success of this platform. It's a barometer of expectations that its technology will prove effective and safe.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772616412686 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
CytomX Therapeutics is developing a new class of anti-cancer antibodies that are activated only in tumors. This increases their safety. This sentiment chart shows how willing investors are to invest in innovative platforms that could spawn a whole family of new drugs, solving fundamental problems in oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772616412701 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CytomX Therapeutics
CytomX Therapeutics is developing a new class of anti-cancer antibodies that are activated only within tumors. This graph shows the financial costs of developing a safer and more effective therapy. It reflects the investment in a platform that can reduce side effects and improve cancer treatment outcomes.
Profit of companies in the market segment - Oncology platforms
CytomX Therapeutics is a biopharmaceutical company developing an innovative platform for creating "smart" cancer drugs that are activated only in tumors. This increases efficacy and reduces side effects. Currently in clinical development, its future profitability depends on the success of this cutting-edge technology.
Overall market profit
CytomX Therapeutics is a biotech company developing a new generation of anti-cancer antibodies that are activated only in tumors. Its value depends on the success of this innovative platform. The overall economic situation, reflected in the chart, critically impacts its ability to attract the capital needed to conduct expensive clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CytomX Therapeutics
CytomX Therapeutics is developing a new class of anticancer drugs called Probody, which are activated only in tumors. This chart reflects analysts' speculative expectations. Future revenue depends on the clinical success of this innovative platform and its ability to improve the safety and efficacy of cancer treatment.
%20profit%20of%20the%20company%20CytomX%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CytomX-Therapeutics&v=1772616412775 "Graph of future (projected) profit of the company CytomX Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology platforms
CytomX Therapeutics is developing an innovative class of anti-cancer drugs that are activated only within tumors, reducing side effects. Profitability forecasts for the oncology sector, shown in the graph, demonstrate the high demand for safer treatments. This chart helps assess how the CytomX platform can transform approaches to cancer therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772616412802 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
CytomX Therapeutics is a biotech company developing a platform for the creation of a new class of anticancer drugs (proantibodies). Its long-term success depends on the results of clinical trials and partnerships. Funding for such innovative platforms is facilitated during periods of market optimism, which accompanies the positive outlook on this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772616412818 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CytomX Therapeutics
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs that are activated only in tumors, reducing side effects. The company may not have commercial revenue. This chart shows how highly investors value its innovative platform, betting on the development of safer and more effective drugs.
P/S market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anticancer drugs—probodies—that are activated only within the tumor environment. This metric reflects the average revenue estimate in the biotech sector and helps understand the market premium for CytomX's innovative platform, which aims to improve the safety of cancer treatments.
P/S of the market as a whole
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs called Probodies. These drugs are activated only in tumors, potentially reducing side effects. This chart helps understand how the market values companies with established revenues, which provides a backdrop for analyzing innovative oncology platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CytomX Therapeutics
CytomX Therapeutics is developing a new class of anti-cancer antibodies that are activated only in tumors. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet that its Probody platform will enable the development of safer and more effective drugs.
%20P%2FS%20CytomX%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CytomX-Therapeutics&v=1772616412886 "The graph of the company's future (projected) P/S CytomX Therapeutics")
Future (projected) P/S of the market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anticancer drugs that are activated directly by tumors. This chart compares market expectations for its future revenue with other oncology platforms. This valuation reflects investors' confidence in the potential of its Probody technology to create safer and more effective drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772616412923 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
CytomX Therapeutics is a biotech company developing a new generation of targeted cancer drugs that are activated only in tumors. Its valuation is based on the potential of this platform. This graph of overall market expectations is irrelevant for CytomX, as its success is determined by scientific innovation, not the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772616412947 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CytomX Therapeutics
This graph illustrates the revenue of CytomX Therapeutics, an oncology company developing innovative "prodrugs" that are activated only within tumors. This reduces toxicity to healthy tissue. Being in the clinical stage, the company has no commercial revenue, and any revenue reflected in the graph is the result of collaborations with major pharmaceutical partners.
Sales of companies in the market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs called Probody, which are activated only within the tumor environment, reducing side effects. This chart shows revenue in the oncology platform sector. It reflects the search for safer and more effective cancer treatments, where CytomX's innovative platform could become the foundation for a new generation of drugs.
Overall market sales
CytomX Therapeutics is developing a new class of targeted anti-cancer drugs—probodies. The company's success depends on the clinical results of this innovative platform. The overall economic situation, reflected in this graph, does not directly impact the need for cancer treatment, but it does influence the investment climate in the biotech sector, which is important for funding R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CytomX Therapeutics
CytomX Therapeutics is an oncology company developing an innovative class of drugs—proantibodies—that are activated directly by tumors. This projected revenue chart reflects confidence in its unique technology. The growth is driven by expectations of successful clinical trial results and partnerships with major pharmaceutical companies.
%20sales%20of%20the%20company%20CytomX%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CytomX-Therapeutics&v=1772616413167 "Schedule of future (projected) sales of the company CytomX Therapeutics")
Future (projected) sales of companies in the market segment - Oncology platforms
CytomX Therapeutics is developing a new class of targeted anticancer drugs called Probody™. These drugs are activated only within the tumor environment, potentially reducing side effects on healthy tissue. This chart shows projected revenues for the entire oncology platform sector, reflecting the search for safer and more effective cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772616413291 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
CytomX Therapeutics is developing a new class of anti-cancer drugs—proantibodies. The company's success depends on clinical results and partnerships with major pharmaceutical companies. The overall economic situation and market sentiment impact the availability of capital for biotech companies to fund innovative research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772616413341 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CytomX Therapeutics
CytomX Therapeutics is developing a new generation of anticancer drugs that are activated directly by tumors. This is a complex scientific endeavor. This chart reflects the cost of innovation. It shows the company's investment in clinical trials of its platform, striving to create safer and more effective drugs.
Market segment marginality - Oncology platforms
CytomX Therapeutics is an oncology company developing a new class of targeted probodies that are activated primarily within tumor cells. This graph reflects its financial performance. For a company in the research stage, outperforming competitors in terms of profitability may be due to upfront payments from major pharmaceutical partners.
Market marginality as a whole
CytomX Therapeutics is developing a new generation of anticancer drugs that are activated directly by tumors. This increases their effectiveness and reduces side effects. The company's success depends entirely on clinical trial results, not on the overall economic indicators reflected in this chart.
Employees in the company, segment and market as a whole
Number of employees in the company CytomX Therapeutics
CytomX Therapeutics is developing a new class of anticancer drugs—proantibodies that are activated only in tumors. This graph shows the team of scientists working on this innovative platform. The growth in staff reflects progress in clinical trials and partnerships with major pharmaceutical companies.
Share of the company's employees CytomX Therapeutics within the market segment - Oncology platforms
CytomX Therapeutics is developing a new generation of anti-cancer antibodies that are activated only in tumors. This cutting-edge science requires a small but elite research team. This statistic underscores the company's focus on innovation: its tiny staff is a concentrated pool of scientific potential, aimed at creating safer drugs.
Number of employees in the market segment - Oncology platforms
CytomX Therapeutics is developing an innovative prodrug platform for oncology, where highly toxic drugs are activated only within the tumor, minimizing side effects. This graph shows the progress of this new class of drugs. The growing number of scientists reflects the expansion of clinical trials and the validation of this promising technology on various cancer types.
Number of employees in the market as a whole
CytomX Therapeutics is developing a new class of anti-cancer antibodies that are activated only in tumors. Its team comprises specialists in biotechnology and oncology. This employment chart demonstrates that growth in cutting-edge science is driven not by macroeconomics, but by the success of the innovative platform and clinical trial results, attracting highly specialized specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CytomX Therapeutics (CTMX)
CytomX Therapeutics is developing a new class of targeted immuno-oncology drugs called probodies. They are activated only within the tumor environment, reducing side effects. This graph demonstrates the enormous cost per employee. This reflects the market's high appreciation for the company's unique technological platform, which could lead to the development of a whole new range of drugs.
%20of%20the%20company%20CytomX%20Therapeutics%20(CTMX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CytomX-Therapeutics-CTMX&v=1772616413626 "Chart of market capitalization per employee (in thousands of dollars) of the company CytomX Therapeutics (CTMX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
CytomX Therapeutics is developing a platform for creating a new class of "smart" cancer drugs—proantibodies. In biotech, this chart represents the market's assessment of the uniqueness of the technology. A high value indicates that investors see enormous potential in their platform, which could make therapy safer and more effective, and they highly value the team behind it.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772616413655 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
CytomX Therapeutics is developing a new class of anti-cancer antibodies that are activated only in tumors. This figure reflects the high cost of innovation in biotechnology. Its market capitalization is based on the potential of this unique platform. The scientific team's efforts could lead to the creation of safer and more effective drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772616413665 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CytomX Therapeutics (CTMX)
CytomX Therapeutics is a biotech company developing prodrugs (probodies) for cancer treatment that are activated only in tumors. They are in the clinical stage and have no revenue from sales. This chart shows the loss per employee—the cost of R&D in one of the most complex areas of oncology.
%20Chart%20CytomX%20Therapeutics%20(CTMX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CytomX-Therapeutics-CTMX&v=1772616413686 "Company Profit Per Employee (in thousands of dollars) Chart CytomX Therapeutics (CTMX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
CytomX Therapeutics is a biotech company whose Probody platform is designed to create safer, more targeted cancer drugs. While in the clinical stage, the company is not profitable. This metric reflects the R&D budget burn per employee. The higher costs may be justified by the complexity of their innovative platform.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772616413749 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
CytomX Therapeutics is a biotech company developing prodrugs (probodies) for cancer treatment that are activated only in tumors. It's a complex scientific platform. This graph shows the negative return on investment (ROI)—the cost of R&D. It reflects how much capital the company spends on its team of scientists to validate this innovative, yet risky, technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772616413782 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CytomX Therapeutics (CTMX)
CytomX Therapeutics is developing an innovative class of anti-cancer antibodies that are activated only in tumors. This schedule is typical for a biotech company in the R&D stage. The lack of revenue per employee means the company is fully focused on clinical trials of its unique Probody platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CytomX-Therapeutics-CTMX&v=1772616413820 "Sales chart per company employee CytomX Therapeutics (CTMX)")
Sales per employee in the market segment - Oncology platforms
CytomX Therapeutics (CTMX) is an oncology company developing prodrugs (probodies) that are activated only within tumors, reducing side effects. This graph shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their unique R&D platform compared to other biotechs.
Sales per employee for the market as a whole
CytomX Therapeutics is a biopharmaceutical company developing "prodrugs" (Probodies™)—antibodies that activate only in tumors, reducing toxicity. It is an R&D platform. This metric reflects their success in securing partnerships (like Astellas), which generate upfront and milestone payments generated by their research team.
Short shares by company, segment and market as a whole
Shares shorted by company CytomX Therapeutics (CTMX)
CytomX Therapeutics is an oncology company developing prodrugs that are activated only within tumors. This chart shows bearish bets. Bears are skeptical of this complex platform, expecting it to fail to prove effective in the clinic or that the company will burn through all its cash before seeing results.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CytomX-Therapeutics-CTMX&v=1772616413982 "Short Shares Chart for the Company CytomX Therapeutics (CTMX)")
Shares shorted by market segment - Oncology platforms
CytomX Therapeutics is a biotech company developing "smart" cancer drugs that activate only in tumors, reducing side effects. This chart shows bearish bets. The "short" bet here is that their complex "Probody" platform will not prove effective in the clinic.
Shares shorted by the overall market
CytomX Therapeutics is developing "smart" antibodies (Probodies) that activate only in tumors, reducing side effects. It's an innovative oncology platform. This chart illustrates the general market fear. When investors panic, they often avoid early-stage biotechs, as the path to profit is long and risky, preferring more predictable sectors.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CytomX Therapeutics (CTMX)
CytomX Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CytomX-Therapeutics-CTMX&v=1772616414087 "RSI 14 indicator chart for the company's stock CytomX Therapeutics (CTMX)")
RSI 14 Market Segment - Oncology platforms
CytomX (CTMX) is a "smart" antibody. Their platform (Probody) creates "masked" (hidden) antibodies that are activated only within the tumor. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is CTMX's volatility a reflection of their platform or general hype?
RSI 14 for the overall market
CytomX (CTMX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CTMX (CytomX Therapeutics)
CytomX (CTMX) is a biotech company developing probodies—masked antibodies that are activated only in tumors. This chart shows the average 12-month forecast. It reflects analysts' confidence in this innovative oncology platform and its clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CTMX-CytomX-Therapeutics&v=1772616414154 "A chart showing analyst consensus forecasts for the expected stock price. CTMX (CytomX Therapeutics)")
The difference between the consensus estimate and the actual stock price CTMX (CytomX Therapeutics)
CytomX is a biotech company that has developed a smart oncology platform. Their drugs (Probodies) are masked prodrugs: they circulate inactive in the body and are activated only when they reach the tumor, which should reduce side effects. This chart shows how much analysts believe in this innovative conditional activation platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CTMX-CytomX-Therapeutics&v=1772616414182 "A chart showing the difference between the consensus forecast and the actual stock price. CTMX (CytomX Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
CytomX Therapeutics is a biotech company developing "smart" antibodies (Probodies) that activate only within tumors, reducing side effects. This chart shows general expectations for the oncology sector. It reflects whether experts believe in this drug-masking technology.
Analysts' consensus forecast for the overall market share price
CytomX Therapeutics (CTMX) is a biopharmaceutical company developing smart cancer drugs. Their Probody platform allows for drug activation only in tumors, sparing healthy tissue. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk research platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CytomX Therapeutics
CytomX is a biotech company working on smart oncology. Their platform (Probody) is a drug cloaking system: their drugs are activated only in the tumor to reduce toxicity. This graph represents pure R&D betting. It likely reflects the market's confidence in their cloaking platform, their partnerships (BMS, Amgen), and their early clinical data.
AKIMA Market Segment Index - Oncology platforms
CytomX (CTMX) is a clinical-stage biotech and a pioneer in oncology. The company is developing the Probody platform, a breakthrough technology for masking antibodies that are activated only within the tumor (reducing toxicity). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough R&D platform (Probody) (CTMX) differentiate it from the average pharma company?
The AKIM Index for the overall market
CytomX is a biotech company and a pioneer in the Probody platform. Its technology allows drugs to be activated only in the tumor microenvironment, reducing toxicity. This chart, reflecting the market average, provides a macro-background. It helps assess how this scientific partnership compares to overall economic trends in oncology.
